Biocon claimed that ADG20 can effectively neutralize a broad range of coronavirus and its emerging variants of concern including the dominant Delta variant.
‘Biocon Biologics gets license to manufacture and commercialize the ADG20, a novel monoclonal antibody-based treatment in India.’
Adagio has published preliminary data from its ongoing Phase 1 trial in healthy volunteers, which supports ADG20’s safety and pharmacokinetic profile and SARS-CoV-2 neutralizing activity.
With its potential to address resistant variants, including the Delta variant, and its ability to be administered easily as a single, intramuscular injection in the outpatient setting, ADG20 is uniquely poised to address the current need for an effective, safe and convenient therapy for COVID-19.
“This partnership with Adagio aligns our joint vision of bringing superior biologic therapies to millions of patients in low- and middle-income countries,” said Kiran Mazumdar-Shaw, Executive Chairperson Biocon Biologics.
“Vaccines alone will not protect and make the world safer. Biologic therapies that arrest the virus in its path of devastation are a necessity for sustainable protection and safety,” Mazumdar-Shaw added.
Under the terms of the deal, Biocon can seek clinical and nonclinical data from Adagio’s emergency use authorisation (EUA) to the US Food and Drug Administration (USFDA). Adagio is likely to seek EUA in the US by as early as the first quarter of 2022.
Source: Medindia
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
